Targeting KRAS mutations in cancer using a novel siRNA delivery technology

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1004146

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Mutations in a gene called KRAS are found in 20% of human cancers but are impossible to target with existing treatments. RNA interference is a promising new way to target genes previously considered undruggable, but there is no way to deliver the molecules required for RNA interference to tumours. We will evaluate the ability of a new nanotechnology based delivery system (antibody targeted minicells) to deliver RNA interference, thereby selectively targeting of KRAS in tumours while avoiding toxicity to normal tissue.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2013

Funding Scheme: NHMRC Project Grants

Funding Amount: $498,899.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

RAS oncogenes | RNA interference | cancer therapy | drug delivery systems | nanotechnology

Related Links